DNA and jolts of electricity get people to make optimal antibodies

The rapid emergence of infectious diseases, highlighted by the COVID-19 and Zika outbreaks, has revealed the challenges we face in keeping pace with viral threats. The swift nature of air travel can facilitate the spread of viruses faster than our ability to create effective treatments. However, the biotechnology sector is rising to meet this challenge, working on innovative technologies aimed at enabling quicker responses to future health threats. Recently, early clinical trial results have emerged from a promising technique that shows potential across a spectrum of infectious diseases. This development underscores the ongoing research and technological advancements aimed at enhancing our preparedness. As new pathogens emerge, they leave behind a diverse array of antibodies generated by both human responses to infections and vaccines, as well as those produced in laboratory animals used for research. While some antibodies exhibit only weak interactions with the pathogens, others are classified as "broadly neutralizing." These powerful antibodies not only attach with high affinity to the original virus but also to many of its variants and related viruses. Once these broadly neutralizing antibodies bind to a pathogen, they effectively inactivate it. This mechanism typically occurs because they target essential sites on the virus's proteins, hindering the pathogen's ability to function. For instance, broadly neutralizing antibodies for HIV interact with proteins that facilitate the virus's entry into immune cells, showcasing their crucial role in combating infections.